SARS-CoV-2 humoral immune response in patients with cardiovascular risk factors: the COmmunity Cohort Study protocol

被引:4
|
作者
Bachelet, Vivienne C. [1 ]
Silva-Ayarza, Ignacio [1 ,2 ]
Lizana, Francisca J. [1 ]
Gomolan, Patricio [1 ]
Silva-Villalobos, Diego [1 ]
Navarrete, Maria S. [1 ]
机构
[1] Univ Santiago de Chile, Escuela Med, Santiago, Chile
[2] Hosp Barros Luco, Dept Infect Dis, Santiago, Chile
来源
BMJ OPEN | 2022年 / 12卷 / 05期
关键词
ANTIBODY-RESPONSES; DISEASE; DURABILITY; BNT162B2; COVID-19; KINETICS; VOCS;
D O I
10.1136/bmjopen-2022-061345
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction The COmmunity Cohort Study aims to determine, after natural exposure to SARS-CoV-2 or anti-SARS-CoV-2 vaccines deployed in Chile to prevent COVID-19 in the context of the current pandemic, the strength and duration of detectable neutralising antibodies in adult ambulatory primary care patients with cardiovascular risk factors. Methods and analysis We will set up a community-based longitudinal, prospective cohort study. The study will be conducted in two public outpatient clinics located in the southern district of Santiago, Chile. We expect to begin recruitment in the second quarter of 2022. Each patient will be followed up for at least 1 year after inclusion in the cohort. The eligible population will be adult patients registered in the Cardiovascular Health Programme. Exposure in this study is defined as any event where participants have contact with SARS-CoV-2 antigens from natural exposure or vaccination. The primary outcomes are seroconversion and strength and duration of the neutralising IgG antibodies to SARS-CoV-2. Secondary outcomes are any COVID-19-related event or intercurrent morbidities or death. Data will be collected by extracting serial blood samples and administering a questionnaire at the first face-to-face contact and monthly follow-up time points. The sample size estimated for this study is 1060. We will characterise the cohort, determine the seroprevalence rate of neutralising antibodies at baseline and determine the rates of antibody decline using a longitudinal mixed-effects model. Ethics and dissemination The Scientific Ethics Committee of the South Metropolitan Health Care Service approved the study protocol (Memorandum No 191/2021). We will present the results in two peer-reviewed publications and national and international professional and academic meetings. We will organise seminars with relevant stakeholders and hold town hall meetings with the local community. We will set up a COmmunity Cohort Study website at www.communitystudy.cl to disseminate the study purpose, research team and milestones.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Poliovirus Vaccination Induces a Humoral Immune Response That Cross Reacts With SARS-CoV-2
    Comunale, Brittany A.
    Engineer, Lilly
    Jiang, Yong
    Andrews, John C.
    Liu, Qianna
    Ji, Lyuqing
    Yurkovich, James T.
    Comunale, Roderick A.
    Xie, Qiyi
    FRONTIERS IN MEDICINE, 2021, 8
  • [42] Humoral Immune Response of SARS-CoV-2-Infected Patients with Cancer: Influencing Factors and Mechanisms
    Esperanca-Martins, Miguel
    Goncalves, Lisa
    Soares-Pinho, Ines
    Gomes, Andreia
    Serrano, Marta
    Blankenhaus, Birte
    Figueiredo-Campos, Patricia
    Catarina-Marques, Ana
    Castro-Barbosa, Ana
    Cardoso, Ana
    Antunes-Meireles, Pedro
    Atalaia-Barbacena, Henrique
    Gaspar, Pedro
    Howell-Monteiro, Patricia
    Pais-de-Lacerda, Antonio
    Mota, Catarina
    Veldhoen, Marc
    ONCOLOGIST, 2021, 26 (09): : E1619 - E1632
  • [43] Humoral Immune Response following SARS-CoV-2 Vaccination in Liver Transplant Recipients
    Timmermann, Lea
    Globke, Brigitta
    Lurje, Georg
    Schmelzle, Moritz
    Schoening, Wenzel
    Oellinger, Robert
    Pratschke, Johann
    Eberspaecher, Bettina
    Drosten, Christian
    Hofmann, Joerg
    Eurich, Dennis
    VACCINES, 2021, 9 (12)
  • [44] Robust memory humoral immune response to SARS-CoV-2 in the tonsils of adults and children
    Altorki, Tarfa A.
    Abdulal, Rwaa H.
    Suliman, Bandar A.
    Aljeraisi, Talal M.
    Alsharef, Asem
    Abdulaal, Wesam H.
    Alfaleh, Mohamed A.
    Algaissi, Abdullah A.
    Alhabbab, Rowa Y.
    Ozbak, Hani
    Eid, Hamza Mohammed
    Almutawif, Yahya Ahmad
    Li, Xuguang
    Al-Rabia, Mohammed W.
    Zhang, Qibo
    Mahmoud, Ahmed Bakur
    Mahallawi, Waleed H.
    Hashem, Anwar M.
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [45] Humoral and adaptive immune responses to the SARS-CoV-2 vaccine
    Rizzo, Roberta
    Bortolotti, Daria
    Morandi, Luca
    Rizzo, Sabrina
    Schiuma, Giovanna
    Beltrami, Silvia
    Papi, Alberto
    Contoli, Marco
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 122 : 412 - 414
  • [46] Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease
    Bitzenhofer, Michaela
    Suter-Riniker, Franziska
    Moor, Matthias B.
    Sidler, Daniel
    Horn, Michael P.
    Gschwend, Anna
    Staehelin, Cornelia
    Rauch, Andri
    Helbling, Arthur
    Joerg, Lukas
    PLOS ONE, 2022, 17 (06):
  • [47] Identifying environmental factors that influence immune response to SARS-CoV-2: Systematic evidence map protocol
    Rayasam, Swati D. G.
    Aung, Max T.
    Cooper, Courtney
    Kwiatkowski, Carol
    Germolec, Dori R.
    Rooney, Andrew A.
    Walker, Vickie R.
    Forte, Chanese
    Woodruff, Tracey J.
    Chartres, Nicholas
    ENVIRONMENT INTERNATIONAL, 2022, 164
  • [48] Humoral immune response to SARS-Cov2 in treated MS patients
    Oreja-Guevara, C.
    Diaz-Diaz, J.
    Gomez-Estevez, I.
    Quezada-Sanchez, J.
    Bullon Sanchez, C.
    Castro-Hernandez, M.
    Oconnor-Perez, S.
    Baos Munoz, E.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 82 - 82
  • [49] Risk factors for and outcomes after SARS-CoV-2 in pregnancy according to disease severity: cohort study with validation of the SARS-CoV-2 diagnosis
    Aabakke, Anna J. M.
    Petersen, Tanja G.
    Krebs, Lone
    Bliddal, Mette
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2023, 102 : 53 - 53
  • [50] Humoral immune response to SARS-CoV-2 third vaccination in patients with multiple sclerosis and healthy controls: A prospective multicenter study
    Krajnc, Nik
    Hegen, Harald
    Traxler, Gerhard
    Leutmezer, Fritz
    Di Pauli, Franziska
    Kornek, Barbara
    Rommer, Paulus
    Zulehner, Gudrun
    Riedl, Katharina
    Duerauer, Sophie
    Bauer, Angelika
    Kratzwald, Sarah
    Klotz, Sigrid
    Winklehner, Michael
    Deisenhammer, Florian
    Guger, Michael
    Hoeftberger, Romana
    Berger, Thomas
    Bsteh, Gabriel
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 65